Cyclosporine Profiling With C2 and C0 Monitoring Improves Outcomes After Heart Transplantation

Journal of Heart and Lung Transplantation

Volumn 25, Issue 5, 2006, Pages 564-568

  Barnard, J B ^a   Thekkudan, J ^a   Richardson, S ^a   Bittar, M N ^a   Martyszczuck, R ^a   Hasan, J ^a   Khasati, N ^a   Keevil, B ^a   Yonan, N ^a  

^a WYTHENSHAWE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; METHYLPREDNISOLONE; STEROID; THYMOCYTE ANTIBODY; CREATININE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; CARDIAC GRAFT REJECTION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; GRAFT SURVIVAL; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MICROEMULSION; NEUROTOXICITY; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; BLOOD; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; GRAFT REJECTION; HEART MUSCLE; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; MONITORING; PATHOLOGY; PHYSIOLOGY; POSTOPERATIVE PERIOD; RETROSPECTIVE STUDY; TIME; TREATMENT OUTCOME;

ADULT; CORONARY DISEASE; CREATININE; CYCLOSPORINE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; MONITORING, PHYSIOLOGIC; MYOCARDIUM; POSTOPERATIVE PERIOD; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 33646123088     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2005.12.005     Document Type: Article

References (25)

1. Carrier M., White M., Pellerin M., Pelletier G.B., and Pelletier L.C. Comparison of Neoral and Sandimmune cyclosporine for induction of immunosuppression after heart transplantation. Can J Cardiol 13 (1997) 469-473
2. Cooney G.F., Jeevanandam V., Choudhury S., et al. Comparative pharmacokinetics of Neoral and Sandimmune in cardiac transplant recipients over one year. Transplant Proc 30 (1998) 1892-1894
3. Tan K.K., Trull A.K., Hue K.L., et al. Pharmacokinetics of cyclosporine in heart and lung transplant candidates and recipients with cystic fibrosis and Eisenmenger's syndrome. Clin Pharmacol Ther 53 (1993) 544-554
4. 2 monitoring strategy for optimising cyclosporin immunosuppression from the Neoral formulation. BioDrugs 15 (2001) 279-290
5. Mahalati K., Belitsky P., Sketris I., West K., and Panek R. Neoral monitoring by simplified sparse sampling area under the concentration-time curve. its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation 68 (1999) 55-62
6. Banner N.R., David O.J., Leaver N., et al. Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery. Transplant Int 15 (2002) 649-654
7. Cantarovich M., Besner J.-G., Barkun J.S., Elstein E., and Loertscher R. Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. Clin Transplant 12 (1998) 243-249
8. International Neoral Renal Transplant Study Group. Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. Am J Transplant 2 (2002) 148-156
9. Cantarovich M., Barkun J.S., Tchervenkov J.I., et al. Comparison of Neoral dose monitoring with cyclosporine trough levels versus 2-hr postdose levels in stable liver transplant patients. Transplantation 66 (1998) 1621-1627
10. Ray J.E., Keogh A.M., McLachlan A.J., and Akhlaghi F. Cyclosporin C(2) and C(0) concentration monitoring in stable, long-term heart transplant recipients receiving metabolic inhibitors. J Heart Lung Transplant 22 (2003) 715-722
11. Delgado D.H., Rao V., Cusimano R.J., et al. Monitoring of cyclosporine 2-hr postdose and trough levels in heart transplantation. J Heart Lung Transplant 21 (2002) 102-103
12. Cantarovich M., Fitchett D., and Latter D.A. Cyclosporine trough levels, acute rejection, and renal dysfunction after heart transplantation. Transplantation 59 (1995) 444-447
13. 2 monitoring in stable renal allograft recipients on maintenance immunosuppression. Nephrol Dial Transplant 19 (2004) 215-222
14. Einecke G., Mai I., Diekmann F., et al. Cyclosporine absorption profiling and therapeutic drug monitoring using C2 blood levels in stable renal allograft recipients. Transplant Proc 34 (2002) 1738-1739
15. Cantarovich M., Elstein E., de Varennes B., and Barkun J.S. Clinical benefit of Neoral dose monitoring with cyclosporine 2-hr postdose levels compared with trough levels in stable heart transplant patients. Transplantation 68 (1999) 1839-1842
16. 2 guided therapeutic drug monitoring of cyclosporin-A in stable heart transplant patients. J Heart Lung Transplant 23 suppl 2 (2004) S107-S108
17. Cantarovich M, Ross H, Arizon JM, et al. A 12-month, multicenter, randomized, adaptive design, open-label study to evaluate the benefit of C2-hr monitoring of Neoral on safety and efficacy outcomes in de novo cardiac transplant recipients receiving basiliximab induction: 6-month results. Am J Transplant (in press).
18. Cockcroft R.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
19. Cole E., Maham N., Cardella C., et al. Clinical benefits of Neoral C2 monitoring in the long-term management of renal transplant recipients. Transplantation 75 (2003) 2086-2090
20. Thervet E., Pfeffer P., Scolari M.P., et al. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion. Transplantation 76 (2003) 903-908
21. Levy G.A., Burra P., Cavallari A., et al. Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on two-hour post dose levels (C2). Transplantation 73 (2002) 953-959
22. Morton J.M., Aboyoun C.L., Malouf M.A., et al. Enhanced clinical utility of de novo cyclosporin C2 monitoring after lung transplantation. J Heart Lung Transplant 23 (2004) 1035-1039
23. Glanville A.R., Hopkins P.M., Aboyoun C.L., et al. Clinical utility of cyclosporin C2 monitoring after lung transplantation (LTX). J Heart Lung Transplant 21 (2002) 143
24. 2 monitoring of cyclosporine in de novo liver transplant recipients. the clinician's perspective. Liver Transplant 10 (2004) 577-583
25. 2 monitoring. a European consensus. Transplant Int 18 (2005) 768-778